SpeeDx trusted assay partner for Cepheid FleXible for the GeneXpert program
ResistancePlus® MG will be the first test available through Cepheid’s FleXible cartridge program. This partnership will increase access for clinicians and support Resistance Guided Therapy in the management of Mycoplasma genitalium.
“With a global installed base of nearly 22,000 GeneXpert Systems, this technology could potentially be applied in multiple settings in which actionable treatment information is needed quickly,” said David H. Persing, M.D., Ph.D., Cepheid’s Chief Medical and Technology Officer.
Read the full press release to learn more.